Kestra Private Wealth Services LLC cut its position in shares of Amedisys, Inc. (NASDAQ:AMED – Get Rating) by 11.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,522 shares of the health services provider’s stock after selling 583 shares during the quarter. Kestra Private Wealth Services LLC’s holdings in Amedisys were worth $779,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also modified their holdings of AMED. Covestor Ltd purchased a new stake in shares of Amedisys during the fourth quarter worth about $28,000. Allworth Financial LP purchased a new stake in shares of Amedisys during the first quarter worth about $38,000. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Amedisys during the first quarter worth about $46,000. Signaturefd LLC grew its holdings in shares of Amedisys by 295.8% during the first quarter. Signaturefd LLC now owns 376 shares of the health services provider’s stock worth $65,000 after buying an additional 281 shares in the last quarter. Finally, Lazard Asset Management LLC purchased a new stake in shares of Amedisys during the first quarter worth about $68,000. 93.36% of the stock is currently owned by hedge funds and other institutional investors.
Amedisys Trading Up 0.3 %
NASDAQ AMED opened at $120.39 on Friday. The company’s fifty day simple moving average is $122.12 and its 200-day simple moving average is $130.49. Amedisys, Inc. has a 52 week low of $101.61 and a 52 week high of $188.88. The company has a current ratio of 0.92, a quick ratio of 0.92 and a debt-to-equity ratio of 0.43. The stock has a market cap of $3.91 billion, a P/E ratio of 28.06, a PEG ratio of 2.93 and a beta of 0.95.
Insider Activity at Amedisys
In related news, insider Denise M. Bohnert sold 557 shares of the company’s stock in a transaction on Thursday, June 23rd. The shares were sold at an average price of $115.00, for a total value of $64,055.00. Following the sale, the insider now directly owns 11,850 shares of the company’s stock, valued at $1,362,750. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.10% of the stock is currently owned by corporate insiders.
Analyst Ratings Changes
A number of equities research analysts recently issued reports on AMED shares. Oppenheimer lowered their target price on shares of Amedisys from $200.00 to $175.00 in a report on Friday, July 29th. Stifel Nicolaus started coverage on shares of Amedisys in a report on Tuesday, June 28th. They issued a “hold” rating and a $128.00 target price for the company. Bank of America downgraded shares of Amedisys from a “neutral” rating to an “underperform” rating and lowered their target price for the company from $145.00 to $102.00 in a report on Tuesday, June 21st. Jefferies Financial Group restated a “buy” rating and issued a $200.00 target price on shares of Amedisys in a report on Tuesday, June 28th. Finally, SVB Leerink lowered their target price on shares of Amedisys from $117.00 to $107.00 and set a “market perform” rating for the company in a report on Tuesday, June 21st. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $156.25.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
- Get a free copy of the StockNews.com research report on Amedisys (AMED)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- No One Told These 3 Stocks It’s a Down Week
- MarketBeat: Week in Review 9/12 – 9/16
- Is There a Cure for What is Ailing Teladoc Stock?
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.